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Anglerfish somatostatin-14 (SS-14) and somatostatin-28 (aSS-28) are derived from pro-somatostatin I (aPSS-I) and pro-somatostatin II (PSS-II), 
respectively. Purified yeast aspartic protease 3 (YAP3), was shown to cleave aPSS-I at the Arg*‘-Lyssz to yield SS-14 and Lys-‘SS-14. In contrast, 
YAP3 cleaved aPSS-II only at the monobasic residue, Arg” to yield aSS-28. Since the paired basic and monobasic sites are present in both 
precursors, the results indicate that the structure and conformation of these substrates dictate where cleavage occurs. Furthermore, the data show 
that YAP3 has specificity for both monobasic and paired basic residues. 
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1. INTRODUCTION 
Neuropeptides and peptide hormones are synthesized 
as larger precursors which are cleaved most commonly 
at paired basic residues and in some cases at monobasic 
sites to yield the biologically active peptides [1,2]. Such 
a mechanism of biosynthesis of various bioactive pep- 
tides extends across different phyla, including yeast, 
mollusks, lower vertebrates and mammals [1,3,4]. Spe- 
cific enzymes that recognize dibasic and monobasic res- 
idues are involved in these processing events [2-4,5]. 
Among the first to be identified and cloned was a yeast 
subtilisin-related serine protease, Kex2, which cleaves 
the paired basic residues of pro-a-mating factor to gen- 
erate a-mating factor [5,6]. Subsequently two mammal- 
ian homologues of Kex2, PClIpC3 and PC2 have been 
cloned and shown to process a number of prohormones 
[4,7-121. Recently, a yeast aspartic protease encoded by 
YAP3, a non-essential gene, has been identified in 
Kex2-deficient mutant and shown to process pro-a- 
mating factor [ 131. YAP3 has been overexpressed, puri- 
fied and characterized as a -70,000 molwt. glycopro- 
tein and is enzymatically active at a pH optimum of 
4.0-4.5. It has been shown to cleave the paired basic 
residues of the mammalian adrenocorticotropin/endor- 
phin prohormone, pro-opiomelanocortin, in vitro [14]. 
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From gene deletion experiments, YAP3 has been impli- 
cated to also cleave at a monobasic site of anglerfish 
pro-somatostatin II to yield the mature hormone, soma- 
tostatin-28, when this prohormone gene was transfected 
into yeast cells [15]. However, confirmation that this 
cleavage activity is mediated by YAP3 awaits in vitro 
studies with the purified enzyme. In the present study, 
we show that purified YAP3 cleaves angle&h pro- 
somatostatin I at the appropriate pair of basic residues 
to yield somatostatin-14, and pro-somatostatin II at the 
monobasic residue to yield somatostatin-28, in vitro. 
2. MATERIALS AND METHODS 
2.1. Preparation of [“S]Cys labeled angle&h pro-somatostatin I 
(aPSS-I) and II (aPSS-II) 
Angler&h islet prohormones, aPSS-I and aPSS-II were radiola- 
beled by incubating islet tissue with [?S]Cys. Tissue homogenates were 
subjected to gel filtration and the prohormones were isolated by high- 
performance liquid chromatography (HPLC) as previously described 
[16,17]. Samples containing aPSS-I and aPSS-II were partially dried 
down using a speed vat concentrator, and used for incubation with 
YAP3 enzyme. The specific activity of each of the precursors aPSS-I 
and aPSS-II was estimated using protein concentrations determined 
from integration of the A,,, UV absorbance peak for each precursor, 
obtained from HPLC chromatograms during purification. The esti- 
mated specific activity of aPSS-I and aPSS-II used in the experiments 
presented was 7.61 x 10’ cpm/pg protein, and 2.92 x 10’ cpm/pg pro- 
tein, respectively. 
2.2. Purification of yeast aspartic protease 3 ( YAP3) activity 
Yeast (S. cerevisiae), strain BJ3501, was transformed with the YAP3 
gene under the control of the galactose promoter as described previ- 
ously [14] and induced by galactose for -20 h. A significant amount 
of expressed YAP3 was secreted into the growth medium (Cawley, 
N.X., unpublished data) and was used as the source of enzyme. The 
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growth medium was collected after removing the cells by centrifuga- 
tion at 2,000 x g. Freshly prepared inhibitors were added (1 mM 
phenylmethanesulfonyl fluoride, 1 mM iodoacetamide and 1 .@rnl 
aprotinin final concentration) to the growth media. YAP3 enzymatic 
activity from the growth medium was purified by concanavalin A 
(ConA, Pharmacia LKB Biotechnology AB, Uppsala, Sweden) affin- 
ity chromatography as described previously [14]. The ConA column 
eluate was desalted on a PD-IO (Sephadex G-25M, Pharmacia LKB) 
column with 20 mM ammonium bicarbonate, 0.02% Tween and con- 
centrated on a Centricon C-30 membrane filter (Amicon Division, 
Beverly, MA 01915). YAP3 activity was determined by the rapid 
I’Z5-/?,,-lipotropin assay as described in Azaryan et al. [14]. ILZS/?,,-LPH 
cleaving enzymatic activity was found in the ConA purified medium 
of induced yeast, which was completely inhibited by pepstatin A. No 
proteolytic activity was found in the growth medium of uninduced 
yeast. 
2.3. Incubation of aPSS-I and aPSS-II with YAP3 and analysis of 
products formed 
Purified YAP3 (-100 ng) was incubated with -4,500 cpm [35S]Cys 
labeled aPSS-I or aPSS-II for 1,2, and 6 h at 37°C in 0.1 M Na citrate 
buffer, pH 4.0 with and without 10e4 M pepstatin A (Sigma, St. Louis, 
MO). The reaction was terminated by the addition of acetic acid to 
a final concentration of 3 M. The products formed were analyzed by 
reverse phase HPLC as previously described [IS]. A 0.1% trifluoroace- 
tic acid/acetonitrile gradient system was used for HPLC and 0.8 ml 
fractions were collected for scintillation counting. 
3. RESULTS 
Incubation of aPSS-II with YAP3 enzyme resulted in 
the cleavage of this substrate to yield somatostatin-28 
(ass-28), but not [Tyr7,Gly’O]SS-14 (Fig. 1). The lack of 
formation of [Tyr7,Gly10]SS-14 was further confirmed 
using a shallower HPLC gradient (identical to Fig. 2) 
which better separated [Tyr7,Gly1qSS-14 from ass-28 
(data not shown). Pepstatin A completely inhibited the 
generation of ass-28 from aPSS-II, indicating that the 
enzymatic activity was due to the aspartic protease, 
YAP3 (Fig. 1). No ass-28 was formed when aPSS-II 
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Fig. 1. HPLC profiles of products generated by incubating aPSS-II 
with YAP3 for 6 h at 37°C in pH 4.0 buffer without (0) and with (H) 
pepstatin A. The arrows show the standards and the dotted line the 
acetonitrile gradient which ran from 20 to 29% in 10 min. 29 to 33% 
in 20 min. and 33 to 39% in 30 min. Y = Tyr; G = Gly. 
600 
apss I 
0 ro i0 i0 i 
Retention time (min) 
Fig. 2. HPLC profiles of products generated by incubating aPSS-I 
with YAP3 for 6 h at 37°C in pH 4.0 buffer without (CI) and with (m) 
pepstatin A. The arrows show the standards and the dotted line the 
acetonitrile gradient which ran from 20 to 39% in 60 min. 
was incubated without YAP3. These results indicate 
that YAP3 cleaved aPSS-II at the monobasic site, Arg73, 
to yield aSS-28, but not at the dibasic, Arg*6-Lys87 site 
to yield [Tyr7,Gly’O]SS-14. 
Fig. 2 shows the cleavage of aPSS-I by YAP3 at the 
paired residues Arg8’-Lys**, to yield SS-14 and [Lyss’] 
SS-14. The formation of these two products indicates 
that YAP3 cleaved on the carboxyl side and in between 
the Arg*l-Lys*’ pair of aPSS-I. However, the ass-28 
product was not observed after a 1 h, 2 h or 6 h incuba- 
tion of PSS-I with YAP3. Pepstatin A completely inhib- 
ited the formation of SS-14 confirming that the cleavage 
at the paired basic residues of aPSS-I was due to the 
aspartic protease YAP3. 
The time course of generation of SS-14 and ass-28 
from aPSS-I and aPSS-II, respectively, by YAP3, was 
analyzed (Fig. 3). Production of SS-14 and ass-28 was 
linear between 1 and 6 h under the incubation condi- 
tions used (2 = 0.98, slope = 54.1 for SS-14 and 
? = 0.99, slope = 271.6 for aSS-28). The rate of genera- 
tion of ass-28 from aPSS-II by YAP3 was five-fold 
greater than the rate of SS-14 formation from aPSS-I. 
Given that the specific activity of aPSS-II is 2.6-fold 
lower than aPSS-I, this is in fact an underestimation. 
4. DISCUSSION 
Previous studies have identified a subtilisin-related 
PCZlike serine protease, purified from angle&h islet 
secretory granules, as the endogenous enzyme that 
cleaves aPSS-I to yield SS-14 [19]. This enzyme also 
cleaved aPSS-II to yield [Tyr7,Gly10]SS-14, a tetrade- 
capeptide analogue of SS-14 [19]. A different enzyme 
was purified from angler&h islet secretory granules that 
processes aPSS-I to SS-28 at the monobasic residue. 
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Fig. 3. Time course of generation of ass-14 from aPSS-I (0) and 
ass-28 from aPSS-II (0). 
This enzyme was characterized as a 39,000 mol.wt. as- 
partic protease with a pH optimum of 4.2 [20]. More 
recently, by the use of deletion mutants of the YAP3 
gene in yeast, it was suggested that an aspartic protease 
encoded by this gene was involved in the processing of 
aPSS-II to ass-28 when the prohormone gene was 
transfected into yeast cells [ 151. Results from the present 
in vitro study unequivocally demonstrate that purified 
YAP3 can specifically cleave the monobasic Arg73 resi- 
due of aPSS-II to generate aSS-28. YAP3 did not ap- 
pear to cleave the monobasic site of aPSS-I, since even 
after only a 1 h incubation the aPSS-I form of SS-28 was 
not observed, although it is possible that the SS-28 if 
generated, was rapidly converted to SS-14. Conversely, 
YAP3 cleaved the dibasic residues Arg*‘-Lys” of aPSS- 
I, but not the equivalent dibasic pair of aPSS-II to gen- 
erate [Tyr7,Gly’O]SS-14 despite the fact that the amino 
acid sequences of the two prohormones are identical in 
the three amino acids upstream and six amino acids 
downstream from the basic pair cleavage site. These 
data clearly indicate that the structure and conforma- 
tion of the substrates play a very important role in 
dictating specificity of cleavage of prohormones. The 
presence of a single basic residue in the -6 position 
(relative to aSS-28) in aPSS-II is consistent with the 
rules governing monobasic cleavage sites [21] and ac- 
counts for the processing at Arg73. The lack of cleavage 
at the monobasic site of aPSS-I may be due to the 
presence of His at position -6 instead of a basic residue. 
Site-directed mutagenesis tudies involving substitution 
of amino acids adjacent to the cleavage sites of human 
prosomatostatin have identified a region located be- 
tween AsnmL2 and G~Y+~ that is important for processing 
the prohormone to SS-14 and SS-28. Specifically, muta- 
tion of the nucleotides encoding prolines (proline is a 
known p-turn blocker) for Ala at the -5 and -9 posi- 
tions within the PSS gene, resulted in a dramatic de- 
crease in processing when the mutated gene was trans- 
fected into Neuro 2A cells, supporting a role for second- 
ary and tertiary structure in directing cleavage of the 
prohormone [22]. It is perhaps the differences in the 
amino acids further upstream from the dibasic cleavage 
sites that account for the differences in cleavage of the 
dibasic residues of the two prohormones by YAP3. 
The ability of YAP3 to cleave aPSS-II at the monoba- 
sic site five times more rapidly than at the dibasic site 
of aPSS-I raises the possibility that the angler&h SS-28 
generating aspartic protease purified from islets may be 
a fish homologue of YAP3. Indeed, a mammalian as- 
partic protease, pro-opiomelanocortin converting en- 
zyme (EC 3.4.23.17), purified from bovine intermediate 
pituitary, with very similar specificity for paired basic 
residues of pro-opiomelanocortin, pH optimum and 
size to YAP3, and shares immunological cross reactivity 
with an antibody against YAP3 has been identified 
[14,23]. Work is now in progress to determine if pro- 
opiomelanocortin converting enzyme will also cleave at 
the monobasic residue of aPSS-II. While YAP3 may 
cleave the monobasic residue of aPSS-II more rapidly 
than the dibasic residues of aPSS-I, this relative differ- 
ence may be only for these two substrates. Further work 
is necessary to determine if YAP3 is generally more 
efficient in cleaving at monobasic than dibasic residues 
of various prohormones. 
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